Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorXingshun Qi

About this trial

Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.

Eligibility criteria

Qualifiers

Patients with liver cirrhosis;

Patients with acute gastrointestinal bleeding presenting with hematemesis, melena, and/or hematochezia;

Adults (age≥18 years old).

Disqualifiers

Components of Child-Pugh, MELD, and CAGIB scores are not available;

In-hospital outcomes are not evaluable.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Xingshun Qi

Lead sponsor

General Hospital of Shenyang Military Region

Sponsor institution